To establish an effective B7-based gene therapy against osteosarcoma, we transferred B7-1/Fas chimeric gene adenovirally into poorly immunogenic osteosarcoma cells. We found that adenovirus-mediated rat B7-1/Fas gene transfer induced (i) expression of rat B7-1/Fas chimeric molecules in osteosarcoma cells, (ii) activation of murine T cells, (iii) apoptosis of murine osteosarcoma cells in the presence of anti-rat B7-1 mAb in vitro, and (iv) therapeutic effects more prominently than B7-1 gene transfer on the development of pulmonary metastasis and survival of mice. These findings collectively support the therapeutic value of adenovirusmediated B7-1/Fas gene transfer on poorly immunogenic osteosarcoma, which is resistant to a treatment protocol using transduction of B7-1 alone.
T reatment of patients with osteosarcoma, especially those resistant to current chemotherapy protocols, has been a major challenge. Active immunotherapy is a potential clue for overcoming such therapeutic difficulties. Using a rat syngeneic model system, we demonstrated that B7-1-transfected tumor vaccine as well as adenovirus-mediated in vivo B7-1 gene transfer induces antitumor immunity against pre-established pulmonary metastasis of osteosarcoma. 1, 2 On the other hand, we also found that B7-1-transfected vaccine has limited efficacy on a poorly immunogenic osteosarcoma cell line. 3 As seen in other studies, 4, 5 the effect of B7-1 costimulation on T-cell-mediated tumor immunity varies depending on the inherent immunogenecity of tumors. To obtain more potent antitumor effects of B7-expressing osteosarcoma vaccine, we constructed a chimeric gene consisting of the extracellular domain of B7-1 and the transmembrane and intracellular domains of Fas, a member of the tumor necrosis factor family acting as an inducer of apoptosis.
Materials and methods

Animals, cell lines and reagents
Male C3H/He and BALB/c mice and LEW rats, 6-week old, were purchased from Japan SLC Inc. (Hamamatsu, Japan), and housed in a specific pathogen-free animal facility in our Institute. A murine osteosarcoma cell line, LM8, derived from Dunn osteosarcoma was kindly provided by the Department of Orthopaedics, Osaka University Graduate School of Medicine. 6 Chinese hamster ovary (CHO) cells expressing murine B7-1 (mB7-1-CHO) were prepared as described previously.
7 LM8 cells were maintained in DMEM (GIBCO, Grand Island, NY) containing 10% fetal calf serum (GIBCO), vitamin solution, sodium pyruvate, nonessential amino acids and l-glutamate at 371C in 5% CO 2 , and mB7-1-CHO cells in aMEM (GIBCO) containing 10% fetal calf serum.
Monoclonal antibodies (mAbs) used were mouse antirat B7-1 mAb (3H5), 8 rat anti-mouse B7-1 mAb (1G10; PharMingen, San Diego, CA), 9 rat anti-mouse MHCclass I (H-2D k ) mAb (15-5-5 ; PharMingen), rat antimouse MHC-class II mAb (1E4; a kind gift from Dr K Ogasawara, Hokkaido University), 10 rat anti-mouse Mac-1 mAb (M1/70; American Type Culture Collection, Rockville, MD), 11 and hamster anti-mouse CD3 mAb (145-2C11; a kind gift of Dr J Bluestone, University of Calfornia, San Francisco). 12 Fusion proteins, CTLA-4Ig and CD28Ig, which consist of an extracellular portion of mouse cytolytic T-lymphocyte-associated antigen-4 (CTLA-4) or CD28 and Fc portion of human immunoglobulin G1, respectively, were prepared as described previously. 13 Construction of B7-1 and B7-1/Fas chimeric cDNAs
The full-length rat B7-1 cDNA was generated from the RNA of LEW rat splenocytes using reverse transcriptionpolymerase chain reaction (RT-PCR) amplification as described previously 2 (Fig 1) . The cDNA fragment encoding the rat Fas (À26 to +1040) was generated from the total RNA of the liver of LEW rats. Briefly, the liver was homogenized in the reagent TRISOL (Life Technologies, Grand Island, NY), and the total RNA was denatured at 701C for 10 minutes in the presence of oligo (dT) as a random primer, and reverse transcribed into cDNA using a SUPERSCRIPTt preamplification system (GIBCO BRL, Tokyo, Japan). PCR was performed using the primer pairs (sense: 5 0 -GGGAACTGCTTTC TCTTTCTGCAG-3 0 , antisense: 5 0 -CATTTTGGTGCCT GTCATAGGTGG-3 0 ) and LA TaqTM polymerase (Takara, Otsu, Japan) under the condition of a 5 minute denaturation at 941C, followed by 30 cycles of 941C for 1 minute, 501C for 1 minute and 721C for 1 minute, and a final extension of 721C for 9 minutes. The amplified fragment was ligated into the PCR II plasmid using a TA cloning kit (Invitrogen, Carlsbad, CA). The resultant PCR II plasmid was amplified and purified by alkaline lysis.
B7/Fas chimeric gene was constructed by a two-step PCR procedure. In the first PCR, two cDNA fragments were generated. Fragment #1 consisting of the extracellular (EC) domain of B7-1 (À15 to +762) and the proximal nine nucleotides of the transmembrane (TM) domain of Fas (511-519) was constructed using the fulllength B7-1 cDNA as the template and the primer pairs (sense: 5 0 -AGAGCATCTGAAGCCATGGCTTAC-3 0 , antisense: 5 0 -CCAAAGGAGCCAGGCAAACGGAATT GTTTG-3 0 ). The underlined oligonucleotide represented the proximal nine nucleotides of the TM domain of Fas. Fragment #2 consisting of the terminal nine nucleotides of the EC domain of B7-1 (754-762) and the TM and intracellular (IC) domains of Fas (511-1040) constructed using the cDNA fragment of Fas (À26 to +1040) as the template and the primer pairs (sense:
. The underlined oligonucleotide represented the terminal nine nucleotides of the EC domain of B7-1. Thus, 18 bases at the 3 0 -end of fragments #1 and those at the 5 0 -end of the fragment #2 corresponded with each other. The PCR condition used was; a 5 minute denaturation at 941C, followed by 10 cycles of 941C for 1 minute, 501C for 1 minute, and 721C for 1 minute, and a final extension of 721C for 9 minutes.
The second PCR was then performed using the mixture of cDNA fragments #1 and #2 as the template, and sense (5 0 -AGAGCATCTGAAGCCATGGCTTAC-3 0 ) and antisense
primers designed to anneal to the 5 0 -ends of the B7-1 and 3 0 -ends of Fas cDNA sequence. The PCR condition used was: a 5 minute denaturation at 941C, followed by 15 cycles of 941C for 1 minute, 501C for 1 minute, and 721C for 1 minute, and a final extension of 721C for 9 minutes. Following sequencing, the amplified 1307 bp fragment was designated as B7-1/Fas chimeric cDNA (Fig 1) .
Preparation of recombinant adenoviral vectors
Recombinant adenovirus vectors encoding the rat B7-1, B7-1/Fas chimeric cDNA, and LacZ cDNA were generated by the COS-TPC method 14 using Adenovirus Expression Vector Kit (Takara), as described previously. 2 As host cells, 293 cells were used to generate a recombinant adenovirus carrying B7-1 or LacZ, and 293-CrmA cells 15 were used to generate a recombinant adenovirus carrying B7-1/Fas. The rat B7-1, B7-1/Fas, and LacZ cDNA fragments were excised from the PCR II plasmids, inserted into cassette cosmid vectors that contained an entire adenovirus type 5 genome, except the E1 and E3 regions, and designated as pAxCA-rB7-1, pAxCA-rB7-1/Fas, and pAxCA-LacZ, respectively. Recombinant adenoviruses were constructed by in vitro homologous recombination in 293 or 293-CrmA cells using the adenovirus DNA terminal protein complex and the cosmid vectors, pAxCA-rB7-1, pAxCA-rB7-1/Fas, or pAxCA-LacZ. The desired recombinant adenoviruses designated Adex-rB7-1, Adex-rB7-1/Fas, and Adex-LacZ were propagated in 293 or 293-CrmA cells and purified by two rounds of cesium chloride density centrifugation. 16 The viruses were dialyzed in phosphate-buffered saline-10% glycerol and the titer of the viruses stock was calculated by a plaque formation assay using 293 or 293-CrmA cells.
Adenoviral gene transfer and flow cytometry
For in vitro adenoviral infection, 1 Â 10 5 LM8 cells were incubated with Adex-rB7-1 and Adex-rB7-1/Fas at the indicated multiplicity of infection (MOI) for 1 hour at 371C in DMEM containing 10% fetal calf serum. Cell surface expression of B7-1 constructs was determined by flow cytometry using 3H5 mAb or CTLA4Ig 48 hour after infection. Flow cytometric analysis was performed by indirect immunofluorescence staining as described before.
2 Cells were incubated with 3H5 mAb or 1G10 mAb or CTLA4Ig for 1 hour at 41C. After washing, cells were incubated with FITC-conjugated goat anti-mouse IgG (Jackson, West Grove, PA) for 3H5 mAb, or FITC-conjugated mouse anti-rat kappa chain mAb (Dainippon Pham. Co. Ltd., Osaka, Japan) for 1G10, or FITC-conjugated goat anti-human IgG (Fcg) (Jackson) for CTLA-4Ig and 
T-cell proliferation assay
Lymph node cells were obtained from CH3/He mice. T cells were purified with a nylon wool column and depletion of MHC class-II and Mac-1-positive cells by complement-dependent cell killing, resulting in T-cell purity of more than 95%. The T-cell proliferation assay was performed as described previously. 7 Briefly, purified mouse T cells (1. 
Induction and detection of cell death in vitro
Cell death was assessed in vitro by MTT assay 17 and DNA fragmentation. 18 In the MTT assay, LM8 cells were seeded into 96-well plates (1 Â 10 4 /well) with Adex-rB7-1 and Adex-rB7-1/Fas at the indicated MOI. After 48 hours, 5 or 10 mg/ml of anti-rat B7-1 mAb was added to the wells and cells were further incubated for 10 hours at 371C in 5% CO 2 . The MTT assay was performed using the Cell Counting Kit-8 (WAKO, Osaka, Japan). In experiments to detect DNA fragmentation, LM8 cells were seeded into culture plates (7.5 Â 10 5 /plate) with Adex-rB7-1 and Adex-rB7-1/Fas at the indicated MOI. After 48 hours, 5 or 10 mg/ml of anti-rat B7-1 mAb was added to the plates and the cells were further incubated for 10 hours at 371C in 5% CO 2 . Cells were then lysed with lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM EDTA pH 8.0, and 0.5% Triton X-100) followed by incubation with 200 mg/ml of RNase A and proteinase K. The supernatant was harvested and DNA was precipitated in 50% isopropyl alcohol with 0.4 M NaCl and subjected to 2% agarose gel electrophoresis with ethidium bromide staining.
Induction and detection of cell death in vivo 2 /2. The number of the pulmonary metastatic nodules in C3H/ He mice was counted 5 weeks after s.c. inoculation. The survival time was determined by allowing the mice to live until they succumbed naturally from the tumor burden, and was analyzed using the Kaplan-Meier estimate.
Four mice were used in each experiment. The statistical significance was determined by Mann-Whitney's U-test and the generalized Wilcoxon test using the statistical analysis software, Statcel (OMS, Tokorozawa, Japan). A probability of o.05 was accepted as a significant difference.
Results
Efficacy of in vitro B7-1/Fas gene transfer into LM8 osteosarcoma cells
To investigate the therapeutic value of B7-1/Fas chimeric molecule on osteosarcoma, we constructed recombinant adenovirus vectors that carry the rat B7-1 cDNA (AdexrB7-1) and B7-1/Fas chimeric cDNA (Adex-rB7-1/Fas), respectively. We first evaluated the efficacy of in vitro gene transfer into a poorly immunogenic murine osteosarcoma cell line, LM8. Flowcytometric analysis using anti-rat B7-1 mAb revealed that infection of LM8 cells with AdexrB7-1 and Adex-rB7-1/Fas resulted in cell surface expression of B7-1 and B7-1/Fas molecules in a dose-dependent manner, respectively (Fig 2) . Notably, larger than 99% of cells expressed B7-1 and B7-1/Fas chimeric molecules when Adex-rB7-1 and Adex-rB7-1/Fas with an MOI of 50 or more was applied. Consistent with the reactivity to anti-B7-1 mAb, CTLA-4 Ig, the soluble form of the B7-1 ligand, also reacted with LM8 cells depending on the MOI of Adex-rB7-1 or Adex-rB7-1/Fas applied. MHC-class I molecules were expressed constitutively on LM8 cells and remained unchanged after infection.
Costimulation of murine T cells by rat B7-1 and B7-1/Fas
To determine whether rat B7-1 and B7-1/Fas properly costimulate murine T cells, purified murine T cells were incubated with a combination of anti-CD3 mAb and Adex-rB7-1-infected LM8 cells or Adex-rB7-1/Fas-infected LM8 cells. As a positive control, CHO cells expressing murine B7-1 (mB7-1-CHO) were used. As shown in Fig 3, incubation with a combination of anti-CD3 mAb and mB7-1-CHO cells, Adex-rB7-1-infected LM8 cells, and Adex-rB7-1/Fas-infected LM8 cells induced proliferation of murine T cells, respectively. The ability to induce T-cell proliferation was indistinguishable between mB7-1-CHO cells and Adex-rB7-1-infected LM8 cells. In contrast, incubation with anti-CD3 mAb alone or incubation with a combination of anti-CD3 mAb and LM8 cells failed to induce significant proliferation of T cells as compared to resting T cells. These findings support the costimulatory role of rat B7-1 and B7-1/Fas in activation of murine T cells.
Induction of apoptosis by B7-1/Fas-mediated signaling
We then examined whether B7-1/Fas-mediated signals induce apoptosis of LM8 cells. As shown in the results of MTT assay (Fig 4a and b) , addition of anti-rat B7-1 mAb impaired the viability of LM8 cells that had been infected with Adex-rB7-1/Fas in a manner depending upon MOI of virus (Fig 4a) or dose of mAb (Fig 4b) , whereas viability of Adex-rB7-1-infected LM8 cells was not affected by anti-rat B7-1 mAb. Moreover, treatment with anti-rat B7-1 mAb induced DNA fragmentation of LM8 cells infected with Adex-rB7-1/Fas, but not those infected with Adex-rB7-1 or Adex-LacZ (Fig 5) .
Induction of apoptosis by in vivo B7-1/Fas gene transfer
Subsequent to in vitro experiments, we examined the effects of B7-1/Fas gene transfer in the induction of tumor cell apoptosis in vivo. Before in vivo experiments, we assessed the reactivity of anti-rat B7-1 mAb with murine B7-1 molecules considering that anti-rat B7-1 mAb may bind to B7-1 on the host antigen presenting cells in vivo.
As shown in Fig 6, mB7-1 -CHO cells bound to antimouse B7-1 mAb, CTLA-4Ig, and CD28Ig, but not at all to anti-rat B7-1 mAb, indicating that anti-rat B7-1 mAb does not crossreact with murine B7-1 molecules.
We then examined apoptosis of LM8 cells 4 days after i.t. injection of Adex constructs. As shown in Fig 7a, injection of Adex-LacZ induced apotosis in 0.63% of LM8 cells as defined by positive staining for annexin V and negative for PI. Injection of Adex-rB7-1 led to apoptosis in 2.25% of LM8 cells (Fig 7b) . In contrast, the number of LM8 cells undergoing apoptosis increased to 6.18% by injection of Adex-rB7-1/Fas (Fig 7c) and 7 .34% by injection of both Adex-rB7-1/Fas and anti-B7-1 mAb (Fig 7d) .
Therapeutic effects of intratumoral injection of AdexrB7-1/Fas on pre-established primary osteosarcoma Finally, we evaluated the therapeutic effects of intratumoral injection of Adex-rB7-1/Fas on pre-established osteosarcoma. As shown in Fig 8a, LM8 cells formed a growing subcutaneous tumor in mice without treatment. An i.t injection of Adex-LacZ did not affect the growth of LM8 tumors as compared with that in untreated mice. In contrast, an i.t injection of Adex-rB7-1 and Adex-rB7-1/ Fas significantly inhibited the growth of subcutaneous LM8 tumors (Po0.05 at 5 weeks) when compared with the growth of tumors injected with Adex-LacZ (Fig 8b) . Systemic administration of anti-B7-1 mAb following injection of Adex-rB7-1/Fas further inhibited the growth of LM8 cells (Po.01 from Adex-LacZ at 5 weeks).
As LM8 cells are capable of forming lethal metastatic lesions, we also examined the effects of adenovirusmediated B7-1/Fas gene transfer and systemic anti-B7-1 mAb treatment in the formation of pulmonary metastatic nodules and survival time of mice. As shown in Fig 9, subcutaneous LM8 tumors receiving intratumoral injection of Adex-LacZ developed pulmonary metastatic nodules of 36.3720.5 at 5 weeks. Intratumoral injection of Adex-B7-1 significantly reduced the number of pulmonary metastatic nodules. Notably, injection of Adex-B7-1/Fas more significantly suppressed the development of pulmonary metastasis than Adex-B7-1 regardless of systemic treatment of anti-B7-1 mAb (Po.03 from Adex-LacZ, Po.05 from Adex-B7-1).
With regard to the survival time, all four mice bearing LM8 tumors and injected Adex-LacZ succumbed due to metastatic disease within 8 weeks (Fig 10) . The survival time of mice was significantly prolonged by injection of Adex-rB7-1/Fas and anti-B7-1 treatment (Po.05), but not by injection of Adex-B7-1 or Adex-B7-1/Fas alone compared to the survival of mice receiving an injection of Adex-LacZ.
Discussion
In the present study, we demonstrated that adenovirusmediated B7-1/Fas chimeric gene (Adex-rB7-1/Fas) transfer into LM8 osteosarcoma cells leads to activation of T cells and apoptosis of LM8 cells upon stimulation with anti-B7-1 mAb in vitro. In addition, a combined therapy using Adex-rB7-1/Fas and anti-B7-1 mAb exerted local and systemic therapeutic effects over syngeneic mice bearing an LM8 tumor more strongly than Adex-rB7-1. Notably, therapeutic effects of Adex-rB7-1/Fas on pulmonary metastasis was significantly higher than We utilized rat B7-1/Fas in a murine osteosarcoma model to avoid the following situation. When murine B7-1/Fas is used in a mouse model, anti-murine B7-1 mAb needs to be used. Then, anti-murine B7-1 mAb presumably binds to B7-1 on the host antigen presenting cells (APCs) and may lead to unfavorable in vivo responses. In contrast, in a murine model with rat B7-1/Fas, anti-rat B7-1 mAb, which does not crossreact with murine B7-1 in FACS analysis (Fig 6) , selectively stimulates B7-1/Fas on osteosarcoma cells in vivo. With respect to the ablitity of rat B7-1 to activate murine T cells, rat B7-1-expressing LM8 cells activated T cells to an extent similar to mouse B7-1-expressing CHO cells (Fig 3) , supporting the interaction between rat-B7-1 and mouse CD28/CTLA-4 on T cells. In addition, the sequence required to bind to CD28 and CTLA-4 has been shown to be conserved between rat B7-1 and murine B7-1. 8 This also theoretically supports our experimental design.
B7-1-expressing tumor vaccines have been implicated to elicit CD8
+ CTLs directly in the absence of help from CD4 + T cells. [20] [21] [22] However, the participation of CD4 + helper T cells is required for the generation of effective CTL responses, 23, 24 in which the indirect pathway mediated by APC, such as dendritic cells play a central role. Induction of osteosarcoma cell apoptosis upon stimulation of B7-1/Fas chimera is advantageous not only for decreasing the tumor burden but also augmenting the processing of tumor debris by APC, which leads to activation of CD4 + T cells in the indirect pathway. It should be noted that the anti-B7-1 mAb (3H5) used to induce apoptosis may simultaneously interfere with the interaction between CD28 on T cells and B7-1/Fas chimera on LM8 cells, 8 thereby inhibiting T-cell activation in the direct pathway. Since Fas is known to exert its cytocidal effect by forming a homotrimer, 25 the mAb reactive with a ligand-binding site of B7-1 is not necessarily required for signaling of B7-1/Fas chimera. In fact, mAbs recognizing a nonligand binding site 26 and synthetic inducers of clustering 27, 28 have been shown to induce apoptosis of cells expressing chimeric proteins containing the IC domain of Fas. Therefore, the use of anti-B7-1 mAbs that do not abrogate ligand binding and alteration in the timing of antibody injection may further improve therapeutic efficacy with the current strategy.
Several studies have demonstrated the synergistic effects of cytokines such as IL-2 29 or IL-12 30 and anti-CTLA-4 blocking mAb 31 on B7-1-expressing tumor vaccines. Besides these extrinsic manipulations of B7-mediated immunity, our previous studies 3, 13 showed that lack of the IgC-like domain of B7-1 resulting from an alternative splicing of mRNA decreases affinity to CTLA- 4 and augments the ability to induce in vivo antitumor immunity. The present study extended such intrinsic manipulation of B7-1 molecules, from physiological (alternative splicing) to artificial molecular engineering.
Since osteosarcoma cell lines are not easily established from individual patients, in vivo transfection of B7-1 gene rather than ex vivo transfection is more suitable for clinical situations. Our previous 2 as well as the present study consistently supported the usefulness of adenovirus vector for transferring B7-1 genes into osteosarcomas.
We used only four mice per each group in the in vivo experiments. Consequently, there were high error bars in experiments assessing the growth of LM8 cells (Fig 8) . These high error bars and small number of mice used are significant limitations of this study.
In summary, we found that adenovirus-mediated rat B7-1/Fas gene transfer induced (i) expression of rat B7-1/Fas chimeric molecules in osteosarcoma cells, (ii) activation of murine T cells, (iii) apoptosis of murine osteosarcoma cells in the presence of anti-rat B7-1 mAb in vitro, and (iv) therapeutic effects more prominent than B7-1 gene transfer on development of pulmonary metastasis and survival of mice. These findings collectively support the therapeutic value of adenovirus-mediated B7-1/Fas gene transfer on poorly immunogenic osteosarcomas to which treatment protocols using transduction of B7-1 alone has limited efficacy. 
Fig 9
Therapeutic effects of B7-1/Fas gene transfer on pulmonary metastasis. The number of pulmonary metastatic nodules were counted at 5 weeks (W) after s.c. inoculation of LM8 cells, followed by treatment with Adex-LacZ, Adex-rB7-1, Adex-rB7-1/Fas, and anti-B7-1 mAb.
Fig 10
Therapeutic effects of B7-1/Fas gene transfer in survival of mice. Mice were inoculated s.c with LM8 cells, followed by treatment with Adex-LacZ, Adex-rB7-1, Adex-rB7-1/Fas, and anti-B7-1 mAb. The survival time of mice was evaluated by allowing the mice to live until they succumbed naturally from the tumor burden, and was analyzed using the Kaplan-Meier estimate. Adenoviral B7-1/Fas chimeric gene transfer H Tsuji et al
